DWTX Projected Dividend Yield
Dogwood Therapeutics Inc ( NASDAQ : DWTX )Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. 21 YEAR PERFORMANCE RESULTS |
DWTX Dividend History Detail DWTX Dividend News DWTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |